أرسل هذا في رسالة قصيرة: Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective

  ____     _    _     ______   __   __   _    _   
 |  _ \\  | || | ||  /_____//  \ \\/ // | || | || 
 | |_| || | || | ||  `____ `    \ ` //  | || | || 
 | .  //  | \\_/ ||  /___//      | ||   | \\_/ || 
 |_|\_\\   \____//   `__ `       |_||    \____//  
 `-` --`    `---`    /_//        `-`'     `---`   
                     `-`